Eli Lilly had a lot riding on its two phase 3 trials of IL-13 inhibitor lebrikizumab in atopic dermatitis (AD) – and it now looks like it has backed a winner. The company has claimed across-the ...

Lebrikizumab, a monoclonal antibody that inhibits an interleukin named IL-13, is especially promising in treatment of this disease. Having been in development by Almirall and Eli Lilly and Company ...

Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at ...

Last August, Eli Lilly began selling the lowest doses of Zepbound — 2.5 mg and 5 mg — in vials rather than the standard auto-injector pen, cutting the price by about half. Now, it’s adding ...

Eli Lilly began offering vials of the two lowest doses of Zepbound, which is typically sold in auto-injector pens, in August last year. On Tuesday, it said it had cut the prices for a month's ...